Evaxion Biotech A/S - ADR

NASDAQ:EVAX  
1.92
+0.09 (+4.92%)
Earnings Announcements

Evaxion Biotech Announces First Quarter 2022 Financial Results And Provides Business Update

Published: 05/11/2022 11:40 GMT
Evaxion Biotech A/S - ADR (EVAX) - Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update.
Evaxion Biotech A/s - As of March 31, 2022, Cash and Cash Equivalents Were $31.4 Million.
Evaxion Biotech A/s - Net Loss for Quarter Ended March 31, 2022 $0.25 Loss per Basic and Diluted Share.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.30

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.33

More details on our Analysts Page.